Advertisement

Topics

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

06:10 EST 9 Jan 2018 | Labiotech.eu

Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to ...

This awesome article Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

NEXT ARTICLE

More From BioPortfolio on "Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...